Next Phase Newsletter

A multi-family office with offices in Asia is joined by a group of families with minimum personal or family asset of 30 million USD. Typical Allocations Size of the firm is around $1.5M. The firm does not have a strict limit to the number of new investments.

The firm is open to investing in general Bio-medical industries, including medical devices, healthcare IT and therapeutics. The firm has a preference for reproductive medicine and eye-related topics. Any kind of technology, device or service are welcomed under these 2 topics. Besides the topics above, the firm is currently looking for pre-clinical and phase I opportunities in therapeutic companies as well as medical devices and healthcare IT companies that are in development. Apart from the bio-medical industry, the firm also focuses on investing in E-Vehicle related startups.

The firm is looking for companies with Asia Angle, preferably Asia-based or those plan to do R&D in Asia. The firm is typically a co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A publicly traded pharmaceutical company is interested in licensing and M&A opportunities in its core therapeutic areas of urology, cardiovascular, gastrointestinal and metabolic diseases, and also in all rare disease/orphan drug assets. The firm will consider partnerships worldwide.  Particularly in the rare disease space, the firm prefers to invest in global rights.

The firm is interested in early stage therapeutic partnerships in rare diseases, including in preclinical assets provided that there is strong preclinical proof of concept data for the asset (such as strong efficacy data from an animal model that are relevant and reflective of the human condition). The firm generally does not invest in rare oncology assets but is otherwise open to a wide range of rare disease opportunities. In other core areas (urology, cardiovascular, gastrointestinal, and  central nervous system) the firm prefers to partner with companies that have obtained solid human proof of concept data. The firm can be a hands-on development and manufacturing partner in small molecule therapeutics, but not in biologics or cell therapies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a diversified business based in Japan is focused on three primary sectors, one of them being healthcare. The team has offices throughout the USA.  The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. They are seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture builder headquartered in Western Europe seeks to build new ventures from scratch, generating innovation in novel science and technology from the earliest stages of development. Currently, the firm is focused on 4 main pillars: energy, agriculture, curative therapeutics, and computation. The firm invests pre-seed/seed capital into the companies they build. The firm will consider global opportunities.

Within life sciences, the firm is indication agnostic and has worked in areas including cystic fibrosis, oncology, neurodegeneration and microbiome. The firm has a strong interest in cell & gene therapy and synthetic biology, but is open to considering all other modalities – the firm has also launched companies that work on a more traditional approach.

In terms of stage of development, the firm invests in the companies it builds at formation stage and is open to working together with other organizations to undertake company creation and support proof-of-concept data generation. The firm generally does not currently build, or invest in, medical devices, diagnostics, or digital health companies.

As a venture builder, the firm does not have strict requirements or expectations on company operations or management team. The firm has generally built companies in Western Europe. That said, the firm has worked with scientists all across the globe to build its companies, and their portfolio also includes companies in other geographies such as the USA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen strategic venture capital fund of big pharma closed at $100 million in 2013, and is managed by a small, dedicated team based in Massachusetts and California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/ neuromodulation device and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

The firm is dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital firm was founded in 2013 with headquarters in Germany. The firm operates from 16 different offices across the globe and has invested in hundreds of companies in a wide variety of sectors. Recently, the firm has been expanding their portfolio in the life science/healthcare sector, and is actively seeking early-stage opportunities. Investing from a $1.5B fund, the firm will typically invest up to $3M as an initial check, with a significant portion of their capital dedicated to follow-on investments. The firm is open to global opportunities, with a focus on USA, Europe, and Asia.

The firm is interested in therapeutics, diagnostics, digital health, and life science tools. The firm’s interest areas also include industrial biotechnology, synthetic biology, and robotics. While the firm does not completely rule out medical device opportunities, they are not a priority for the firm. Within therapeutics, the firm will consider both single assets and platform technologies. In general, the firm is stage and indication agnostic.

The firm has no specific company or management team requirements and is open to working with all types of management teams. The firm can act as a lead, co-lead, or co-investor, and provides operational support for their portfolio companies to help them scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture capital company was founded in 2005 and located in California. The firm manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.